Latest From RESprotect GmbH
Summer is for relaxing, but biotechnology companies like Avion Pharmaceuticals and investors like DRI Capital remain focused on licensing key programs or buying new revenue streams.
SciClone Pharmaceuticals has returned the North American rights to the anticancer drug RP101 to privately owned German oncology firm RESprotect which it obtained in 2007.
Acuvax has divested to an unnamed European company its 10% holding in the private German oncology firm RESprotect. The Australian venture retains an interest in RESprotect's lead project, RP101 (BVdU), which is being developed by SciClone Pharmaceuticals.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- RESprotect GmbH
- Senior Management
Rudolf Fahrig, PhD, CEO
Torsten Fahrig, COO & CFO
Jörg-Christian Heinri, PhD, CSO
Klaus Kutz, MD, CMO
- Contact Info
Phone: (49) 351 20250643
Krippener Str. 18b
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.